Online inquiry

IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10891MR)

This product GTTS-WQ10891MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL1A gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC), Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000575.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552
UniProt ID P01583
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10891MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1033MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ13658MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ4909MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ4271MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ10201MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ4583MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ3162MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ16015MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZW-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW